Patents Represented by Attorney, Agent or Law Firm Ted K. Ringsred
  • Aerosol formulation containing a diol-diacid derived dispersing aid
    Patent number: 6042811
    Abstract: A medicinal aerosol formulation containing a particulate drug and a diol/diacid condensate as a dispersing aid.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: March 28, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: Daniel C. Duan, James S. Stefely, David W. Schultz, Chester L. Leach
  • Medicinal inhalation aerosol formulations containing budesonide
    Patent number: 6039932
    Abstract: A pharmaceutical aerosol formulation, suitable for administration by oral or nasal inhalation, containing a suspension of particulate budesonide, hydrofluoroalkane propellant and, optionally, additional hydrofluoroalkane propellants, surfactant selected from oleic acid, sorbitan oleates and lecithin, and adjuvant have a Kauri-butanol value of at least 10.
    Type: Grant
    Filed: September 25, 1997
    Date of Patent: March 21, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: Nayna Govind, Philip A. Jinks, Danna L. Ross, Gary H. Ward
  • Immune response modifier compounds for treatment of TH2 mediated and related diseases
    Patent number: 6039969
    Abstract: Immune response modifier compounds--imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines--are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: March 21, 2000
    Assignee: 3M Innovative Properties Company
    Inventors: Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
  • Seal configuration for aerosol canister
    Patent number: 6036942
    Abstract: An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: March 14, 2000
    Assignee: 3M Innovative Properties Company
    Inventor: Todd D. Alband
  • Container for aerosol formulation
    Patent number: 6030682
    Abstract: A container for aerosols which contains 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, or a mixture thereof as a propellant, wherein the container has at least one elastomeric sealing member comprising a thermoplastic copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers which may be 1-butene, 2-hexene, and 1-octene.
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: February 29, 2000
    Assignee: 3M Innovative Properties Company
    Inventor: Paul E. Marecki
  • Device for delivering an aerosol
    Patent number: 6006745
    Abstract: A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 28, 1999
    Assignee: Minnesota Mining and Manufacturing Company
    Inventor: Paul E. Marecki
  • Process for preparing imidazoquinolinamines
    Patent number: 5998619
    Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: December 7, 1999
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom
  • Flunisolide aerosol formulations
    Patent number: 5980867
    Abstract: Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: November 9, 1999
    Assignee: 3M Innovative Prperties Company
    Inventors: Tsi-Zong Tzou, Robert K. Schultz, Danna L. Ross
  • 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines
    Patent number: 5977366
    Abstract: 1-substituted, 2-substituted 1H-imidazo[4,5-c]-quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce biosynthesis of interferon, and they inhibit tumor formation in animal models. This invention also provides intermediates for preparing such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: November 2, 1999
    Assignee: 3M Innovative Properties Company
    Inventors: John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
  • Gel formulations for topical drug delivery
    Patent number: 5939090
    Abstract: Pharmaceutical gel formulations for topical drug delivery include drug, colloidal silicon dioxide, triacetin and, preferably, propylene glycol. The gel formulations are well suited for topical delivery of the drug 4-amino-2-ethoxymethyl-.alpha.,.alpha.-dimethyl-1H-imidazo?4,5-c!quinoline -1-ethanol, which when applied topically induces cytokines, such as interferon and tumor necrosis factor, locally in the skin or mucous membranes of a mammal. The gel formulations are also well-suited for topical delivery of drugs for treatment of diseases involving skin and/or mucosal lesions because the gel formulations do not need to include irritating components.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: August 17, 1999
    Assignee: 3M Innovative Properties Company
    Inventors: Joseph M. Beaurline, Patrick J. Roddy, Mark A. Tomai
  • Transmucosal delivery system
    Patent number: 5908637
    Abstract: A device for delivering a heparinic anticoagulant across a mucosal surface in order to achieve or maintain a therapeutically effective blood level of the heparinic anticoagulant. The device involves a matrix containing a therapeutically effective amount of a heparinic anticoagulant, and a mucoadhesive or other mechanism for maintaining the matrix in contact with the mucosal surface for a time sufficient to allow release of the heparinic anticoagulant to the mucosal surface.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: June 1, 1999
    Assignee: Minnesota Mining and Manufacturing Co.
    Inventors: Luce R. M. Benes, Francoise L. R. B. Horriere
  • Aerosol actuator
    Patent number: 5899201
    Abstract: A hand held aerosol actuator involving an aerosol source and a chamber having walls defining a constriction aperture. The aerosol source communicates with the chamber and directs an aerosol dose along an axis into the chamber. The constriction aperture is coaxial with the exit orifice and is dimensioned such that the respirable mass of the aerosol dose is increased relative to the respirable mass of an aerosol dose expelled through a like actuator not having the constriction aperture.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: May 4, 1999
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Robert K. Schultz, Constantinos Sioutas
  • Fused cycloalkylimidazopyridines
    Patent number: 5886006
    Abstract: 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines that induce interferon (.alpha.) biosynthesis in human cells. Also disclosed are pharmaceutical compositions containing such compounds and methods of inducing interferon (.alpha.) biosynthesis and treating viral infections involving the use of such compounds.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: March 23, 1999
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Nick Nikolaides, John F. Gerster
  • Intravaginal treatment of vaginal infections with buffered metronidazole compositions
    Patent number: 5840744
    Abstract: A non-flowing composition and method for treatment of bacterial vaginosis are disclosed. An afflicted vagina is treated with a therapeutically effective but relatively low dose of metronidazole in a composition that includes a buffer system maintaining the composition at a pH value in the range of about 3.75 to about 4.25. The composition can also be used for prophylactic purposes.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: November 24, 1998
    Assignee: Minnesota Mining and Manufacturing Co.
    Inventor: Robert J. Borgman
  • Seals for use in an aerosol delivery device
    Patent number: 5836299
    Abstract: A device for delivering an aerosol, comprising: a casing member, a valve stem, and a diaphragm. The diaphragm is made of an ethylene-propylene-diene rubber ("EPDM") and is stable to dimensional change when exposed to 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoroethane.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: November 17, 1998
    Assignee: Minnesota Mining & Manufacturing Co.
    Inventor: Oh-Seung Kwon
  • Transmucosal drug delivery device
    Patent number: 5780045
    Abstract: A transmucosal drug delivery device in the form of a sheet material. The device contains an acid-containing particulate polymeric resin dispersed throughout a polytetrafluoroethylene support matrix.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: July 14, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Roy L. McQuinn, Joan K. Barkhaus
  • Seal configuration for aerosol canister
    Patent number: 5775321
    Abstract: A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: July 7, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventor: Todd D. Alband
  • Medicinal aerosol formulations
    Patent number: 5776434
    Abstract: A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: July 7, 1998
    Assignee: Riker Laboratories, Inc.
    Inventors: Tarlochan S. Purewal, David J. Greenleaf
  • Flunisolide aerosol formulations
    Patent number: 5776433
    Abstract: Pharmaceutical aerosol formulations substantially free of chlorofluorocarbons and comprising a therapeutically effective amount of flunisolide in solution with ethanol and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof are used for the treatment of bronchial asthma. The formulation may be delivered by a metered dose inhaler with a canister that is inert to flunisolide.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 7, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Tsi-Zong Tzou, Robert K. Schultz, Danna L. Ross
  • Beclomethasone solution aerosol formulations
    Patent number: 5776432
    Abstract: Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: July 7, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Robert K. Schultz, David W. Schultz